Solid self-nanoemulsifying cyclosporine a pellets prepared by fluid-bed coating: Stability and bioavailability study

Journal of Biomedical Nanotechnology

Volumn 8, Issue 3, 2012, Pages 515-521

  Lei, Yang ^a,b   Qi, Jianping ^a   Nie, Sufang ^b   Hu, Fuqiang ^c   Pan, Weisan ^b   Lu, Yi ^a   Wu, Wei ^a  

^a FUDAN UNIVERSITY   (China)

^b SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^c ZHEJIANG UNIVERSITY   (China)

Author keywords

Cyclosporine A; Fluid bed coating; Oral bioavailability; Pellets; Self nanoemulsifying; Solid; Stability

Indexed keywords

ACCELERATED TESTING; BIOAVAILABILITY STUDY; CO-SURFACTANTS; CYCLOSPORINE A; DRUG DELIVERY SYSTEM; FLUID-BEDS; HIGH TEMPERATURE; IN-VITRO; IN-VIVO; MOISTURE ABSORPTION; ORAL BIOAVAILABILITY; PROOF OF CONCEPT; PVP K-30; SELF-NANOEMULSIFYING; STRESS TESTING;

BIOCHEMISTRY; COATINGS; CONVERGENCE OF NUMERICAL METHODS; DRUG DELIVERY; LIQUIDS; ORE PELLETS; SOLIDS; SURFACE ACTIVE AGENTS;

PELLETIZING;

CYCLOSPORIN A;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; EMULSION; HUMIDITY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MOISTURE; NONHUMAN; PARTICLE SIZE; SELF NANOEMULSIFYING DRUG DELIVERY SYSTEM; SINGLE DRUG DOSE; TEMPERATURE MEASUREMENT; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; BIOLOGICAL AVAILABILITY; CRYSTALLIZATION; CYCLOSPORINE; DOGS; EMULSIONS; MATERIALS TESTING; METABOLIC CLEARANCE RATE; NANOCAPSULES; PARTICLE SIZE; SURFACE PROPERTIES;

EID: 84862291314     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2012.1400     Document Type: Article

References (36)

1. D. Patel and K. K. Sawant, Oral bioavailability enhancement of acyclovir by self-microemulsifying drug delivery systems (SMEDDS). Drug Dev. Ind. Pharm. 33, 1318 (2007).
2. J. Cui, B. Yu, Y. Zhao, W. W. Zhu, H. L. Li, H. X. Lou, and G. X. Zhai, Enhancement of oral absorption of curcumin by self-microemulsifying drug delivery systems. Int. J. Pharm. 371, 148 (2009).
3. W. Wu, Y. Wang, and L. Que, Enhanced bioavailability of silymarin by self-microemulsifying drug delivery system. Eur. J. Pharm. Biopharm. 63, 288 (2006).
4. Y. Lu, J. P. Qi, and W. Wu, Absorption, disposition and pharmacokinetics of nanoemulsions. Curr. Drug Metab. (accepted).
5. C. W. Pouton, Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and 'self-microemulsifying' drug delivery systems. Eur. J. Pharm. Sci. 11, S93 (2000).
6. A. J. Humberstone and W. N. Charman, Lipid-based vehicles for the oral delivery of poorly water soluble drugs. Adv. Drug Deliver. Rev. 25, 103 (1997).
7. B. K. Kang, J. S. Lee, S. K. Chon, S. Y. Jeong, S. H. Yuk, G. Khang, H. B. Lee, and S. H. Cho, Development of self-microemulsifying drug delivery systems (SMEDDS) for oral bioavailability enhancement of simvastatin in beagle dogs. Int. J. Pharm. 274, 65 (2004).
8. E. Franceschinis, D. Voinovich, M. Grassi, B. Perissutti, J. Filipovic-Grcic, A. Martinac, and F. Meriani-Merlo, Self-emulsifying pellets prepared by wet granulation in high-shear mixer: Influence of formulation variables and preliminary study on the in vitro absorption. Int. J. Pharm. 291, 87 (2005).
9. C. Tuleu, M. Newton, J. Rose, D. Euler, R. Saklatvala, A. Clarke, and S. Booth, Comparative bioavailability study in dogs of a self-emulsifying formulation of progesterone presented in a pellet and liquid form compared with an aqueous suspension of progesterone. J. Pharm. Sci. 93, 1495 (2004).
10. S. Nazzal and M. A. Khan, Controlled release of a self-emulsifying formulation from a tablet dosage form: Stability assessment and optimization of some processing parameters. Int. J. Pharm. 315, 110 (2006).
11. S. Nazzal and M. A. Khan, Response surface methodology for the optimization of ubiquinone self-nanoemulsified drug delivery system. AAPS PharmSciTech 3, E3 (2002).
12. S. Nazzal, Smalyukh, II, O. D. Lavrentovich, and M. A. Khan, Preparation and in vitro characterization of a eutectic based semisolid self-nanoemulsified drug delivery system (SNEDDS) of ubiquinone: Mechanism and progress of emulsion formation. Int. J. Pharm. 235, 247 (2002).
13. V. Agarwal, A. Siddiqui, H. Ali, and S. Nazzal, Dissolution and powder flow characterization of solid self-emulsified drug delivery system (SEDDS). Int. J. Pharm. 366, 44 (2009).
14. K. L. Christensen, G. P. Pedersen, and H. G. Kristensen, Physical stability of redispersible dry emulsions containing amorphous sucrose. Eur. J. Pharm. Biopharm. 53, 147 (2002).
15. G. Dollo, P. Le Corre, A. Guerin, F. Chevanne, J. L. Burgot, and R. Leverge, Spray-dried redispersible oil-in-water emulsion to improve oral bioavailability of poorly soluble drugs. Eur. J. Pharm. Sci. 19, 273 (2003).
16. K. L. Christensen, G. P. Pedersen, and H. G. Kristensen, Preparation of redispersible dry emulsions by spray drying. Int. J. Pharm. 212, 187 (2001).
17. P. Balakrishnan, B. J. Lee, D. H. Oh, J. O. Kim, M. J. Hong, J. P. Jee, J. A. Kim, B. K. Yoo, J. S. Woo, C. S. Yong, and H. G. Choi, Enhanced oral bioavailability of dexibuprofen by a novel solid Self-emulsifying drug delivery system (SEDDS). Eur. J. Pharm. Biopharm. 72, 539 (2009).
18. T. Yi, J. L. Wan, H. B. Xu, and X. L. Yang, A new solid self-microemulsifying formulation prepared by spray-drying to improve the oral bioavailability of poorly water soluble drugs. Eur. J. Pharm. Biopharm. 70, 439 (2008).
19. M. Newton, J. Petersson, F. Podczeck, A. Clarke, and S. Booth, The influence of formulation variables on the properties of pellets containing a self-emulsifying mixture. J. Pharm. Sci. 90, 987 (2001).
20. J. M. Newton, M. R. Pinto, and F. Podczeck, The preparation of pellets containing a surfactant or a mixture of mono- and di-gylcerides by extrusion/spheronization. Eur. J. Pharm. Sci. 30, 333 (2007).
21. A. Abdalla and K. Mader, Preparation and characterization of a self-emulsifying pellet formulation. Eur. J. Pharm. Biopharm. 66, 220 (2007).
22. Y. Lei, Y. Lu, J. P. Qi, S. F. Nie, F. Q. Hu, W. S. Pan, and W. Wu, Solid self-nanoemulsifying cyclosporin A pellets prepared by fluid-bed coating: Preparation, characterization and in vitro redispersibility. Int. J. Nanomedicine 6, 795 (2011).
23. J. Lai, Y. Lu, Z. Yin, F. Hu, and W. Wu, Pharmacokinetics and enhanced oral bioavailability in beagle dogs of cyclosporine A encapsulated in glyceryl monooleate/poloxamer 407 cubic nanoparticles. Int. J. Nanomedicine 5, 13 (2010).
24. P. Guan, Y. Lu, J. Qi, M. Niu, R. Lian, F. Hu, and W. Wu, Enhanced oral bioavailability of cyclosporine A by liposomes containing a bile salt. Int. J. Nanomedicine 6, 965 (2011).
25. Z. Cai, Y. Wang, L. J. Zhu, and Z. Q. Liu, Nanocarriers: A general strategy for enhancement of oral bioavailability of poorly absorbed or pre-systemically metabolized drugs. Curr. Drug Metab. 11, 197 (2010).
26. X. W. Wei, C. Y. Gong, M. Y. Gou, S. Z. Fu, Q. F. Guo, S. Shi, F. Luo, G. Guo, L. Y. Qiu, and Z. Y. Qian, Biodegradable poly(ε-caprolactone)- poly(ethylene glycol) copolymers as drug delivery system. Int. J. Pharm. 381, 1 (2009).
27. B. Wang, M. Gou, X. Zheng, X. Wei, C. Gong, X. Wang, Y. Zhao, F. Luo, L. Chen, Z. Qian, and L. Yang, Co-delivery honokiol and doxorubicin in MPEG-PLA nanoparticles. J. Nanosci. Nanotechnol. 10, 4166 (2010).
28. L. C. Chang, C. L. Wu, C. W. Liu, W. H. Chuo, P. C. Li, and T. R. Tsai, Preparation, characterization and cytotoxicity evaluation of tanshinone IIA nanoemulsions. J. Biomed. Nanotechnol. 7, 558 (2011).
29. C. A. Dehelean, S. Feflea, S. Ganta, and M. Amiji, Anti-Angiogenic Effects of Betulinic Acid Administered in Nanoemulsion Formulation Using Chorioallantoic Membrane Assay. J. Biomed. Nanotechnol. 7, 317 (2011).
30. N. Jain, S. Akhter, G. K. Jain, Z. I. Khan, R. K. Khar, and F. J. Ahmad, Antiepileptic intranasal Amiloride loaded mucoadhesive nanoemulsion: Development and safety assessment. J. Biomed. Nanotechnol. 7, 142 (2011).
31. B. D. Tarr and S. H. Yalkowsky, Enhanced Intestinal-Absorption of Cyclosporine in Rats through the Reduction of Emulsion Droplet Size. Pharm. Res. 6, 40 (1989).
32. P. C. De Smidt, M. A. Campanero, and I. F. Troconiz, Intestinal absorption of penclomedine from lipid vehicles in the conscious rat: Contribution of emulsification versus digestibility. Int. J. Pharm. 270, 109 (2004).
33. S. P. Yap and K. H. Yuen, Influence of lipolysis and droplet size on tocotrienol absorption from self-emulsifying formulations. Int. J. Pharm. 281, 67 (2004).
34. F. S. Nielsen, K. B. Petersen, and A. Mullertz, Bioavailability of probucol from lipid and surfactant based formulations in minipigs: Influence of droplet size and dietary state. Eur. J. Pharm. Biopharm. 69, 553 (2008).
35. C. J. Dunn, A. J. Wagstaff, C. M. Perry, G. L. Plosker, and K. L. Goa, Cyclosporin: An updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral®)1 in organ transplantation. Drugs 61, 1957 (2001).
36. K. S. Lown, R. R. Mayo, A. B. Leichtman, H. L. Hsiao, D. K. Turgeon, P. Schmiedlin-Ren, M. B. Brown, W. Guo, S. J. Rossi, L. Z. Benet, and P. B. Watkins, Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin. Pharmacol. Ther. 62, 248 (1997).